Gonzalo Artiach's questions to AstraZeneca PLC (AZN) leadership • Q2 2025
Question
Gonzalo Artiach of Danske Bank inquired about AstraZeneca's confidence in tozorakimab for COPD following mixed competitor data in the IL-33 space, and asked for details on the onselimab patient subgroup that showed positive results.
Answer
EVP of Biopharmaceuticals R&D, Sharon Barr, expressed confidence in tozorakimab, highlighting its differentiated profile that inhibits signaling through both ST2 and RAGE-EGFR pathways, which is important for COPD. CEO of Alexion, Marc Dunoyer, described the onselimab subgroup as a 'sizable minority' that saw a 'very meaningful' clinical benefit, but declined to provide further details ahead of a formal data presentation.